Harmony Net Tangible Assets from 2010 to 2026
| HRMY Stock | USD 36.01 0.16 0.45% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 278.2 M | Current Value 292.1 M | Quarterly Volatility 250.4 M |
Check Harmony Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Harmony Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 55.9 M, Net Interest Income of 988.5 K or Depreciation And Amortization of 16.4 M, as well as many indicators such as Price To Sales Ratio of 2.99, Dividend Yield of 0.0 or PTB Ratio of 2.81. Harmony financial statements analysis is a perfect complement when working with Harmony Biosciences Valuation or Volatility modules.
Harmony | Net Tangible Assets | Build AI portfolio with Harmony Stock |
The evolution of Net Tangible Assets for Harmony Biosciences Holdings provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Harmony Biosciences compares to historical norms and industry peers.
Latest Harmony Biosciences' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Harmony Biosciences Holdings over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Harmony Biosciences' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Harmony Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Harmony Net Tangible Assets Regression Statistics
| Arithmetic Mean | (82,692,948) | |
| Coefficient Of Variation | (302.79) | |
| Mean Deviation | 217,902,885 | |
| Median | (242,673,000) | |
| Standard Deviation | 250,387,934 | |
| Sample Variance | 62694.1T | |
| Range | 787.1M | |
| R-Value | 0.80 | |
| Mean Square Error | 24252.1T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | 39,584,994 | |
| Total Sum of Squares | 1003105.9T |
Harmony Net Tangible Assets History
About Harmony Biosciences Financial Statements
Harmony Biosciences investors use historical fundamental indicators, such as Harmony Biosciences' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Harmony Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 278.2 M | 292.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.